2000 Central Avenue
Suite 100
Boulder, CO 80301
United States
720 505 4755
https://ir.frtx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 4
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Albert Nicholas Marchio II | CEO, CFO, Secretary & Chairman | 251,83k | N/D | 1952 |
Aron Aizenstat M.B.A., P.M.P. | Vice President of Corporate Development & Operations | N/D | N/D | N/D |
Mr. Aaron Fox-Collis CPA | VP of Finance & Chief Accounting Officer | N/D | N/D | N/D |
Ms. Sue Fattor | Head of Human Resource | N/D | N/D | N/D |
Dr. James S. McElvain Ph.D. | Interim Head of CMC Development | N/D | N/D | N/D |
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
L'ISS Governance QualityScore di Fresh Tracks Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.